keyword
MENU ▼
Read by QxMD icon Read
search

Psoriasis quality of life

keyword
https://www.readbyqxmd.com/read/28722209/reporting-of-outcomes-in-randomised-controlled-trials-on-nail-psoriasis-a-systematic-review
#1
REVIEW
C I M Busard, J Y C Nolte, M C Pasch, Ph I Spuls
Harmonization of outcome measures is needed to increase the value of clinical trials on nail psoriasis. To provide the first step in core outcome set (COS) development, a systematic review was conducted to identify outcome domains and instruments reported in (ongoing) randomised controlled trials (RCTs) on nail psoriasis. Identified outcome domains included clinical signs, quality of life, symptoms and delivery of care. A NAPSI was most commonly used to assess clinical signs (73.8% of studies). Other outcome instruments used included the NAS, composite fingernail score, a physician global assessment, individual nail features or a combination of these...
July 19, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28714180/tofacitinib-for-the-treatment-of-moderate-to-severe-chronic-plaque-psoriasis-in-japanese-patients-subgroup-analyses-from-a-randomized-placebo-controlled-phase-3-trial
#2
Masatoshi Abe, Chikako Nishigori, Hideshi Torii, Hironobu Ihn, Kei Ito, Makoto Nagaoka, Naoki Isogawa, Isao Kawaguchi, Yukiko Tomochika, Mihoko Kobayashi, Anna M Tallman, Kim A Papp
Tofacitinib is an oral Janus kinase inhibitor. These post-hoc analyses assessed tofacitinib efficacy and safety in Japanese patients with psoriasis enrolled in a 52-week global phase 3 study. Patients received tofacitinib 5 mg, tofacitinib 10 mg or placebo twice daily (b.i.d.); placebo-treated patients advanced to tofacitinib at week 16. Primary efficacy end-points were the proportions of patients with 75% or more reduction from baseline Psoriasis Area and Severity Index (PASI-75) and Physician's Global Assessment (PGA) of "clear" or "almost clear" (PGA response) at week 16...
July 17, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28711022/pre-clinical-efficacy-assessment-of-malva-sylvestris-on-chronic-skin-inflammation
#3
Arthur S Prudente, Graziela Sponchiado, Daniel A G B Mendes, Bruna S Soley, Daniela A Cabrini, Michel F Otuki
In the search for improved quality of life, the treatment of skin diseases like psoriasis (hyperproliferative disease) is valid, since it causes huge social discomfort to the patient. In this context, earlier studies showed that Malva sylvestris L. has anti-inflammatory activity demonstrated by acute animal models of skin inflammation, becoming a promising target for further studies. The present investigation aimed to verify the effect of hydroalcoholic extract of M. sylvestris (HEMS) on the chronic inflammatory and hyperproliferative response caused by multiple applications of 12-O-tetradecanoylphorbol-13-acetate (TPA) on mouse ears...
July 12, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28694859/interplay-between-prolactin-and-pathogenesis-of-psoriasis-vulgaris
#4
Delia Botezatu, Mihaela Tovaru, Simona-Roxana Georgescu, Oana-Diana Leahu, Calin Giurcaneanu, Antoanela Curici
INTRODUCTION: The polypeptide hormone prolactin (PRL) represents the pituitary modulator of lactation and reproduction. Currently, we discuss the wide range of PRL actions "beyond the mammary horizon". Multiple studies had showed the role of PRL as a cytokine, with comparable structural motifs, similar receptor structures and signal transduction pathways. Almost two decades ago it was fi rst hypothesized that PRL acts as a neuroendocrine modulator of both skin epithelial growth and the skin immune system...
September 2016: Mædica
https://www.readbyqxmd.com/read/28689165/tear-film-and-ocular-surface-assessment-in-psoriasis
#5
Emanuela Aragona, Laura Rania, Elisa Imelde Postorino, Alberto Interdonato, Roberta Giuffrida, Serafinella Patrizia Cannavò, Domenico Puzzolo, Pasquale Aragona
BACKGROUND: Psoriasis is a skin disease with also systemic involvement: its impact on the eye is not well established and often clinically underestimated. Aim of this study was to investigate the presence of ocular discomfort symptoms and of ocular surface changes in a population of patients with psoriasis. METHODS: For this cross-sectional, comparative study, 66 patients with psoriasis were subdivided according to the presence of arthritis and to the use of biological therapy...
July 8, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28686974/phytotherapeutic-potential-of-natural-herbal-medicines-for-the-treatment-of-mild-to-severe-atopic-dermatitis-a-review-of-human-clinical-studies
#6
REVIEW
Zahid Hussain, Hnin Ei Thu, Ahmad Nazrun Shuid, Prashant Kesharwani, Shahzeb Khan, Fahad Hussain
For many decades, natural herbal medicines, polyherbal formulations and/or decoctions of plant-derived materials have widely been accepted as alternative complementary therapies for the treatment, cure or prevention of a wide range of acute and chronic skin diseases including chronic herpes, prurigo, acute and chronic wounds, psoriasis and atopic dermatitis (AD). This review was aimed to summarize and critically discuss about the therapeutic viability and clinical applicability of natural herbal medicines for the treatment of AD in human...
July 4, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28681230/probiotics-prebiotics-and-synbiotics-for-the-treatment-and-prevention-of-adult-dermatological-diseases
#7
REVIEW
Manisha Notay, Negar Foolad, Alexandra R Vaughn, Raja K Sivamani
BACKGROUND: Probiotic, prebiotic, and synbiotic supplementation is becoming more prevalent nowadays. Clinical studies have demonstrated some of the medical benefits of probiotics, prebiotics, and synbiotics within dermatology but an evidence-based review of their effects in adults is needed. OBJECTIVE: The aim of this study was to identify evidence for the use of supplementation with probiotics, prebiotics, or synbiotics for the prevention and treatment of dermatological diseases in adults...
July 5, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28673565/monocyte-subpopulations-study-in-patients-with-plaque-psoriasis
#8
Mariana Carvalho Costa, Bruno de Oliveira Rocha, Camilla Sampaio Paixão, Maria de Fátima Santos Paim de Oliveira, Lícia Maria Henrique da Mota, Lucas Pedreira de Carvalho
Psoriasis is a chronic and systemic, immune-mediated, inflammatory disease, mainly manifested by skin and / or joints lesions, presenting with a wide degree of clinical severity, but generally with great impact on patients' quality of life. Despite advances in the understanding of its pathogenesis, especially regarding the participation of T-lymphocytes and the key role of TNF, the triggering factor of the disease at the molecular level remains unknown, as well as the function of other cell populations. By presenting antigens to T-lymphocytes, monocytes assume an important role in both innate and adaptive immune response...
July 2017: Medical Hypotheses
https://www.readbyqxmd.com/read/28667200/quality-of-life-treatment-satisfaction-and-efficacy-of-non-biological-systemic-therapies-in-patients-with-plaque-psoriasis-study-protocol-for-a-prospective-observational-study
#9
Christine Fink, Timo E Schank, Nina Trenkler, Lorenz Uhlmann, Knut Schäkel
INTRODUCTION: Psoriasis vulgaris often leads to a significant impaired quality of life and dissatisfaction with the existing therapeutic approaches. However, patients' quality of life and treatment satisfaction are of utmost importance, since it is positively related to therapy adherence and encourages patient's compliance. The study described herein evaluates the quality of life, treatment satisfaction and efficacy during the initial 6 months of treatment with a non-biological systemic agent in a real-life clinical setting...
June 30, 2017: BMJ Open
https://www.readbyqxmd.com/read/28659016/calcipotriene-betamethasone-dipropionate-aerosol-foam-in-the-treatment-of-plaque-psoriasis-a-review-of-the-literature
#10
Jillian Frieder, Dario Kivelevitch, Alan Menter
Psoriasis is a common chronic immune-mediated skin disease which has a significant impact on patients' quality of life, and is associated with numerous comorbidities (i.e., psoriatic arthritis, Crohn's disease and cardiovascular disease). A greater understanding of its immunopathogenesis has guided the development of novel, more targeted therapies. Nonetheless, traditional treatment with topical agents, phototherapy and systemic medications is used in the management of the majority of psoriasis patients. Mainstay topical treatments include corticosteroids and vitamin D derivatives...
June 29, 2017: Therapeutic Delivery
https://www.readbyqxmd.com/read/28656915/clinical-and-serological-characteristics-of-nail-psoriasis-in-indian-patients-a-cross-sectional-study
#11
Deepashree Daulatabad, Chander Grover, Bineeta Kashyap, Amit Kumar Dhawan, Archana Singal, Iqbal R Kaur
BACKGROUND: Nail involvement in psoriasis is common with a lifetime incidence of 80-90%. It may reflect severity of cutaneous involvement and predict joint disease. Yet it remains, poorly studied and evaluated especially in Indian psoriatic patients. AIM: The present study was undertaken to evaluate clinical and serological profile of nail involvement in psoriasis and to assess quality of life impairment associated with nail involvement in Indian patients. METHODS: Consecutive patients with nail psoriasis were assessed for severity of cutaneous disease (psoriasis area severity index score) and nail disease (nail psoriasis severity index score)...
June 28, 2017: Indian Journal of Dermatology, Venereology and Leprology
https://www.readbyqxmd.com/read/28652702/spotlight-on-ixekizumab-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-design-development-and-use-in-therapy
#12
REVIEW
Alessandro Giunta, Alessandra Ventura, Maria Sole Chimenti, Luca Bianchi, Maria Esposito
Psoriasis is a chronic inflammatory disease affecting up to 3% of the general population, associated with discomfort and impaired quality of life. In recent years, the pathogenic cytokine network of psoriasis has been extensively studied leading to the development of new treatments that provide greater efficacy. Interleukin 17A (IL-17A) has been recognized as a crucial cytokine that mediates immunopathogenesis of psoriasis. Ixekizumab - indicated for the treatment of adults with moderate-to-severe plaque psoriasis - is a subcutaneously administered humanized monoclonal antibody that targets IL-17A...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28646610/measuring-the-societal-impact-of-psoriasis-in-the-united-kingdom-through-a-non-interventional-study-of-patients
#13
C E Griffiths, R Williams, A C Halliday, J A Leman
This cross-sectional study aimed to measure total societal costs of moderate-to-severe, chronic plaque psoriasis in adults, and was conducted at 10 National Health Service hospitals in the United Kingdom between June-November 2014. Data capture was via hand-held electronic devices. Investigators at participating sites identified participants. Eligible patients were ≥18 years of age and diagnosed with moderate-to-severe plaque psoriasis for at least 6 months (Psoriasis Area and Severity Index (PASI) ≥10, and Dermatology Life Quality Index (DLQI) >10)...
June 24, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28635026/efficacy-and-safety-of-ixekizumab-treatment-in-japanese-patients-with-moderate-to-severe-plaque-psoriasis-subgroup-analysis-of-a-placebo-controlled-phase-3-study-uncover-1
#14
Shinichi Imafuku, Hitoe Torisu-Itakura, Atsushi Nishikawa, Fangyi Zhao, Gregory S Cameron
The present study describes a subgroup analysis of 33 Japanese patients participating in UNCOVER-1, an international, placebo-controlled, phase 3 study of ixekizumab in patients with moderate-to-severe psoriasis. Patients were randomized to a placebo (n = 13) or ixekizumab 80 mg every 4 (IXEQ4W, n = 12) or 2 (IXEQ2W, n = 8) weeks, from week 0-12. At week 12, ixekizumab-treated patients with a static Physician Global Assessment score 0 or 1 (sPGA [0,1]; n = 16) were re-randomized to a placebo (n = 6), ixekizumab 80 mg every 12 (IXEQ12W, n = 5) or 4 (IXEQ4W, n = 5) weeks, from week 12-60...
June 21, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28620064/sleep-disturbance-in-psoriatic-disease-prevalence-and-associated-factors
#15
Ian T Y Wong, Vinod Chandran, Suzanne Li, Dafna D Gladman
OBJECTIVE: We aimed to determine the prevalence and quality of sleep in patients with psoriatic arthritis (PsA) and those with psoriasis without PsA (PsC) followed in the same center, to identify factors associated with sleep disturbance, and to compare findings to those of healthy controls (HC). METHODS: The study included 113 PsA [ClASsification for Psoriatic ARthritis (CASPAR) criteria] and 62 PsC (PsA excluded by a rheumatologist) patients and 52 HC. Clinical variables were collected using a standard protocol...
June 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28609161/the-efficacy-of-short-term-clobetasol-lotion-in-the-treatment-of-scalp-psoriasis
#16
Ali Rajabi-Estarabadi, Hournaz Hasanzadeh, Arash Taheri, Steven R Feldman, Alireza Firooz
BACKGROUND: Scalp psoriasis can have a considerable impact on patients' quality of life and is considered difficult to treat. Treatment failure may, however, be due to poor adherence, as application of topical treatments to hair bearing areas is difficult and time consuming and also poor commination between physician and patient. OBJECTIVE: To assess the efficacy of short term treatment of scalp psoriasis with topical clobetasol lotion. MATERIALS AND METHODS: 12 patients with mild to severe scalp psoriasis were recruited for this study...
June 13, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28608530/psoriasis-in-latin-america-and-the-caribbean-a-systematic-review
#17
REVIEW
A Hernández-Vásquez, L Molinari, N Larrea, A Ciapponi
BACKGROUND: Psoriasis is a chronic inflammatory disease that generally affects the skin, nails and joints. The burden of psoriatic disease in Latin America and the Caribbean (LAC) remains largely unknown. OBJECTIVE: To estimate the burden of psoriasis in LAC. METHODS: We conducted a systematic review following the MOOSE and PRISMA statements. We searched published studies in MEDLINE, EMBASE, LILACS, and CENTRAL from January 1, 2000 to August 5, 2015...
June 13, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28606711/impact-of-atopic-dermatitis-on-health-related-quality-of-life-and-productivity-in-adults-in-the-united-states-an-analysis-using-the-national-health-and-wellness-survey
#18
Laurent Eckert, Shaloo Gupta, Caroline Amand, Abhijit Gadkari, Puneet Mahajan, Joel M Gelfand
BACKGROUND: Given its public health impact, there is need for broad and representative data on the humanistic burden of atopic dermatitis (AD). OBJECTIVE: To establish the humanistic burden of AD in US adults. METHODS: Data were from the 2013 US National Health and Wellness Survey; AD self-reports were propensity-matched with non-AD controls and with psoriasis controls. Bivariate analyses were conducted on burden outcomes between the AD and control groups...
August 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28602039/secukinumab-demonstrates-greater-sustained-improvements-in-daily-activities-and-personal-relationships-than-ustekinumab-in-patients-with-moderate-to-severe-plaque-psoriasis-52-week-results-from-the-clear-study
#19
A Blauvelt, K Reich, S Mehlis, F Vanaclocha, H Sofen, W Abramovits, Y Zhao, I Gilloteau, E Davenport, N Williams, A Guana, S Tyring
BACKGROUND: Psoriasis can greatly impact patients' lives by influencing clothing worn as well as by impairing sexual functioning. Secukinumab, a human monoclonal antibody selectively neutralizing interleukin-17A, has demonstrated good efficacy and safety in the treatment of moderate-to-severe psoriasis and psoriatic arthritis with a rapid onset of action and sustained response. OBJECTIVE: This analysis using the CLEAR study, a phase 3b double-blind study comparing the efficacy and safety of secukinumab versus ustekinumab in adults with moderate-to-severe plaque psoriasis, evaluated the treatment effects on patient's daily activities and personal relationships...
June 11, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28597182/apremilast-a-novel-oral-treatment-for-psoriasis-and-psoriatic-arthritis
#20
REVIEW
Tiago Torres, Luis Puig
Psoriasis is a chronic immune-mediated disease associated with several co-morbidities and negative impacts on a patient's quality of life. Despite the advances in biologic therapy, there are still unmet needs in the treatment of psoriasis, as current treatments are limited in terms of long-term efficacy, tolerability, safety, route of administration, and cost. Apremilast is an oral, small-molecule phosphodiesterase 4 inhibitor that works intracellularly by blocking the degradation of cyclic adenosine 3',5'-monophosphate, resulting in increased intracellular cyclic adenosine 3',5'-monophosphate levels in phosphodiesterase 4-expressing cells...
June 8, 2017: American Journal of Clinical Dermatology
keyword
keyword
65639
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"